Delta opioid receptors represent a promising target for the development of novel analgesics. A number of tools have been developed recently that have significantly improved our knowledge of d receptor function in pain control. These include several novel d agonists with potent analgesic properties, and genetic mouse models with targeted mutations in the d opioid receptor gene. Also, recent findings have further documented the regulation of d receptor function at cellular level, which impacts on the pain-reducing activity of the receptor. These regulatory mechanisms occur at transcriptional and post-translational levels, along agonist-induced receptor activation, signaling and trafficking, or in interaction with other receptors and neuromodulatory systems. All these tools for in-vivo research, and proposed mechanisms at molecular level, have tremendously increased our understanding of d receptor physiology, and contribute to designing innovative strategies for the treatment of chronic pain and other diseases such as mood disorders.
Introduction
Morphine and other related opiates are potent analgesics widely used for pain treatment. These compounds act on opioid receptors to inhibit pain transmission and perception. The three opioid receptors, m, d and k receptors, are transmembrane G-proteins coupled receptors encoded by Oprm1, Oprd1 and Oprk1 genes, respectively (Kieffer and Gaveriaux-Ruff, 2002; Stevens, 2009) . Opioid receptors are activated endogenously by the opioid peptides enkephalins, b-endorphin and dynorphins processed from large precursor proteins encoded by Penk, Pomc and Pdyn genes (Akil et al., 1998) . The opioid system plays a central role in pain control, and in reward (Mendez and MoralesMulia, 2008; Shippenberg et al., 2008; Rodriguez-Arias et al., 2010) and neuroprotection (Chao and Xia, 2010; Johnson and Turner, 2010) . In addition, this system regulates a number of physiological functions that include respiration and gastrointestinal transit, as well as endocrine and immune systems (Kieffer and Gaveriaux-Ruff, 2002; Sauriyal et al., 2010) .
As for the initial molecular cloning (Evans et al., 1992; Kieffer et al., 1992) , a number of tools have been developed enabling better understanding of d receptor function in nociception and pain. Research on d opioid analgesia has benefited from a series of novel agonists that extend the panel of pharmacological tools available to study d receptors in pain control. Mouse genetic models have been created, that harbor targeted mutations of the receptor. These mice represent unique tools for assessing both the endogenous pain-reducing d tone and the implication of d receptors in the actions of opioid as well as nonopioid analgesics. These tools will be presented here, together with novel mechanisms for the development of therapeutic strategies targeting the d opioid receptor.
In addition, there was tremendous progress in understanding how d receptor expression and activity are regulated, and these mechanisms heavily contribute to d analgesia. Receptor regulation takes place at different levels, including genomic and transcriptional controls in the nucleus, post-translational events in the cytoplasm and endoplasmic reticulum, interaction of d receptors with other receptors at the cell membrane, and processes that follow d receptor activation within the cell, and these aspects will be discussed.
Altogether, d opioid receptor research represents a very active field of investigation, with about 1000 publications within the last five years. This review therefore cannot be exhaustive and only recent reviews or publications are cited.
Delta opioid analgesia: from early pharmacology to novel agonists
In early opioid pharmacology, two peptidic agonists (2-Dpenicillamin, 5-D-penicillamin)-enkephalin (Mosberg et al., 1983) and deltorphin (Kreil et al., 1989) were most frequently used to study d receptor function in pain control (Chang et al., 2004) . However, their peptidic nature prevented their use by systemic administration in vivo. Later, the nonpeptidic agonists BW373U86 and SNC80 (Bilsky et al., 1995; Chang et al., 2004) , and the antagonist naltrindole (Portoghese et al., 1988; Chang et al., 2004) proved to be more stable ligands in vivo to investigate d receptor-mediated analgesia.
The identification of several novel d agonists has further broadened the repertoire of molecules available to study d receptors in vivo (Vanderah, 2010; Pradhan et al., 2011) . Over the past decade, SB-235863 (Petrillo et al., 2003) , DValAla-Enk (Brainin-Mattos et al., 2006) , NIH 11082 (Aceto et al., 2007) , AR-M100390 (Pradhan et al., 2009 ), ADL5859 (Le Bourdonnec et al., 2008 , ADL5747 (Le Bourdonnec et al., 2009 ), JNJ-20788560 (Codd et al., 2009 , compound 8e (Jones et al., 2009) and KNT-127 (Saitoh et al., 2011) have been developed as analgesics in preclinical models. Table 1 summarizes the analgesic effects of these novel agonists in several pain models, as well as analgesic effects of previously described reference molecules such as (2-D-penicillamin, 5-D-penicillamin)-enkephalin, (D-Ser2,Leu5)-enkephalin, deltorphin, SNC80 or Tan-67. Altogether, the data cited in Table 1 indicate that d receptor activation diminishes chronic pain in the three mouse, rat, and monkey species. Table 1 also shows that several distinct chronic pain models are sensitive to d agonists, including inflammatory, neuropathic, cancer, and diabetic pain. Moreover, d receptor activation reduces hypersensitivity in heat, cold, and mechanical modalities. Altogether, d opioid agonists efficiently decrease chronic pain in many preclinical models and clinical trials will validate their translational potential to patients.
Mouse genetic models to study d receptor function in vivo
Delta opioid receptor knockout mice A major step for understanding d receptor function was the generation of mice with a targeted inactivation of the Oprd1 gene, or d receptor knockout mice (Zhu et al., 1999; Filliol et al., 2000) . A prime finding with these mutant mice was the discovery that d receptors play a critical role in the control of emotional responses (Filliol et al., 2000) , revealing anxiolytic and antidepressant activities of the receptor that were further confirmed by the pharmacology (Jutkiewicz, 2006; Noble and Roques, 2007; Javelot et al., 2010; Pradhan et al., 2011) . This mouse line represents a unique genetic tool to assess both the influence of endogenous d receptor tone on pain physiology, and the in-vivo selectivity of known or new d agonists.
Delta receptor knockout mice showed no change or only subtle alterations in their sensitivity to acute pain (Filliol et al., 2000; Martin et al., 2003; Contet et al., 2006; Nadal et al., 2006; Gaveriaux-Ruff et al., 2008; Pradhan et al., 2011) and stress-induced analgesia developed normally (Contet et al., 2006) . Interestingly, however, d receptor knockout mice showed augmented neuropathic and inflammatory pain (Nadal et al., 2006; Gaveriaux-Ruff et al., 2008) , suggesting that endogenous d opioid activity alleviates chronic pain. Altogether, data from the genetic approach are in agreement with the notion that d agonists barely modulate acute nociception, but are most efficient under conditions of persistent pain (see below). SNC80-induced analgesia was abolished in d receptor knockout animals in a model of inflammatory hyperalgesia induced by Complete Freund's Adjuvant . These data confirmed the in-vivo selectivity of the compound previously proposed by the pharmacology (Chang et al., 2004) .
Interestingly, chronic treatment with tricyclic antidepressants, which produce antiallodynic effects in a neuropathic pain model, was ineffective in d receptor knockout mice (Benbouzid et al., 2008) . These data revealed the implication of d receptors for the analgesic effects of tricyclic antidepressants in neuropathic pain situations. The implication of endogenous opioid mechanisms in this particular activity of antidepressant drugs was specifically mediated by d receptors, as the compounds were fully effective in m receptor knockout animals (Bohren et al., 2010) . Along this line, antiallodynia induced by chronic b2-agonists was blocked by the d receptor antagonist naltrindole suggesting an interaction between b2-adrenergic and d receptor systems. In the future, d receptor knockout mice may help to reveal the interaction of d receptor with other receptor systems in pain control.
Conditional knockout mice lacking delta opioid receptors in Nav1.8 nociceptive neurons
Under chronic pain, d receptor activation produces analgesia at different sites within nociceptive circuits. Delta agonists are effective when administered systemically, intrathecally, intracerebroventricularly, or into the rostral ventromedial medulla or Nucleus Raphe Magnus (Fig. 1) . A potent analgesia was also obtained at the periphery where nociceptive processing is initiated, and opioid receptors of the peripheral nervous system are proposed as therapeutic targets to limit the centrallymediated adverse effects of opiates. First trials have been promising (Stein et al., 1990) and the field of peripheral opioid receptors has gained importance lately (Stein et al., 2009; Hua and Cabot, 2010) .
To inactivate genes specifically in nociceptive primary afferents, a conditional knockout strategy has been reported for the cannabinoid CB1 receptor (Agarwal et al., 2007) and Nav1.7 channel (Nassar et al., 2004) . The approach was based on the Cre-Lox system and used a mouse line expressing Cre recombinase in Nav1.8 + sensory neurons that include unmyelinated C and thinly myelinated Ad nociceptive neurons. The same driver Cre line was used recently to inactivate Oprd1 in these neurons and examine whether peripheral d receptors contribute to pain control (Gaveriaux-Ruff et al., 2011).
In conditional knockout mutants, analgesia induced by intraperitoneal SNC80 treatment was abolished under both inflammatory and neuropathic conditions, revealing the essential role of peripheral d receptors in systemic d opioid analgesia. These peripheral receptors are not necessarily sufficient to produce the full analgesic response, as d receptors expressed in peripheral non-Nav1.8 dorsal root ganglion (DRG) neurons, at the level of spinal cord or in the brain (Ossipov et al., 2010) may also participate in systemic d analgesia. The results nevertheless support the notion that developing peripherally-acting d agonists is a feasible strategy for the design of novel effective analgesics devoid of centrally-mediated side effects. 
Knock-in mice expressing a functional green fluorescent d opioid receptor
A unique genetic mouse model was developed, to investigate the distribution of d receptors throughout the nervous system, and the link between receptor localization at a subcellular level and receptor function in vivo. In these mice, endogenous d receptors are replaced by delta receptors in fusion with green fluorescent protein (DOReGFP) using a knock-in strategy (Scherrer et al., 2006) . DOR-eGFP mice express fully functional d receptors, which are directly visible in vivo. Fluorescent d receptors are expressed in DRGs, spinal cord and brain (Scherrer et al., 2006 , with profiles in accordance with results from in-situ hybridization (Mansour et al., 1995; Mennicken et al., 2003) and ligand binding autoradiography (Goody et al., 2002) . In models of inflammatory pain, DOR-eGFP mice respond to d agonist-induced analgesia as control wild-type mice (Pradhan et al., 2009 (Pradhan et al., , 2010 . These animals have been instrumental in deciphering differential internalizing properties of the two d agonists SNC80 and AR-M100390 throughout the nervous system in vivo, and elucidating short-term and long-term consequences of ligand-biased receptor trafficking on analgesic responses (see details below and (Pradhan et al., 2009 (Pradhan et al., , 2010 .
Delta receptor expression and function are regulated at different levels within the cell A major factor contributing to d opioid analgesia is the expression level of the receptor protein at the cell surface of neurons, and at the different sites of the painprocessing pathways. Variations in receptor density may result from sequence variations within the Oprd1 gene, transcriptional regulation, post-translational events or receptor trafficking to and fro the plasma membrane.
Genetic variability
Sequence variants within the Oprd1 gene may influence d receptor expression across individuals, and may contribute to interindividual differences in responses to d drugs (Lotsch and Geisslinger, 2011) . In the human gene, several single nucleotide polymorphisms have been identified (Kim et al., 2006) . The T80G variant in exon 1, occurring at an allele frequency of 0.08, leads to a Phe27Cys substitution in the extracellular N-terminal domain, and has been associated with pain sensitivity (Kim et al., 2006) . In heterologous expression systems, the Cys27 variant showed lower maturation efficiency, increased accumulation of receptor precursors in pre-Golgi compartment and faster constitutive internalization (Leskela et al., 2009) . Other human single nucleotide polymorphism variants showed no association with pain sensitivity (Kim et al., 2006; Huang et al., 2008; Zhang et al., 2010) . In the mouse Oprd1 gene, polymorphism was identified in mice selectively bred for high and low stress-induced analgesia, and later shown to differ also in basal nociception and opioid analgesia. In this study, three polymorphic sites were detected in the Oprd1 coding region (Sacharczuk et al., 2010) . Among these, the C320T transition resulted in an (23) ADL5747 (21) DPDPE (11) Sites for d opioid analgesia. This scheme summarizes sites where delta agonist administration induces analgesia in animal models of chronic pain (see Table 1 (Bilsky et al., 1995) , , (Kabli & Cahill, 2007) ; (4) (Pacheco & Duarte, 2005) , (Obara et al., 2009) , (Joseph & Levine, 2010) , (Gaveriaux-Ruff et al., 2011); (5) (Stein et al., 1989) , (Zhou et al., 1998) , (Hervera et al., 2009) , (Hervera et al., 2010) ; (6) , (Cahill et al., 2001) , (Mika et al., 2001) , , (Pradhan et al., 2006) , (Gendron et al., 2007a; Gendron et al., 2007b) , , (Beaudry et al., 2009) , (Dubois & Gendron, 2010) , (Otis et al., 2011) ; (7) 
Transcriptional regulation
Pathological situations like chronic pain, inflammation, and nerve damage were shown to induce transcriptional regulation of the d receptor that may impact on receptor activity. Transcription factors binding to Oprd1 promoter sequences and regulating gene expression, as well as epigenetic aspects, have recently been reviewed extensively (Wei and Loh, 2011) . Regulation at the transcriptional level of d receptor expression was investigated in several models of chronic pain and seems highly variable depending on a series of factors including (a) the pain model, (b) the receptor localization (brain, spinal cord, DRG, sciatic nerve, or skin), (c) time points considered after pain initiation, (d) the animal strain (Herradon et al., 2008) and (e) the technique used for detecting receptor expression. Data are summarized in Table 2 . In the different models of inflammatory pain, no change, upregulation or downregulation of d receptor mRNA levels were reported. In models of neuropathic pain also, several regulation patterns were observed and together the data indicate that regulation at transcriptional level may be detectable in specific pain situations, and likely impact on d receptor protein levels (Table 2) . Most expression studies were performed at the level of DRG and spinal cord. Delta receptor activity, as measured by agonist-induced G protein activation, was also altered in the cingulate, cortex, and amygdala under conditions of inflammatory and neuropathic pain (Narita et al., 2006a (Narita et al., , 2006b ). This particular regulation in the central nervous system was suggested to contribute to chronic paininduced emotional dysfunction (Narita et al., 2006a (Narita et al., , 2006b . Finally, d receptor expression was highly increased under two clinical pain conditions, in the skin of fibromyalgia patients (Salemi et al., 2007) and in hypertrophic scars (Cheng et al., 2008) . Collectively the data show that d receptor expression is regulated under (Lynch et al., 2008) experimental chronic pain, and more investigations in pain patients are needed to correlate findings in animal models with clinical situations.
Post-translation regulation
A third level of regulation occurs post-translationally in receptor protein maturation and transport. Mechanisms for d receptor folding and integration into membranes were investigated using heterologous expression systems. Tuusa et al. (2010) recently showed that d receptor biogenesis is regulated early after translation at the level of endoplasmic reticulum by the molecular chaperone calnexin and the sarcoendoplasmic reticulum calcium ATPase SERCA2b in a calcium and ATP dependent manner. Delta receptor targeting from the endoplasmic reticulum to the cell surface was further proposed to require the golgi chaperone receptor transport protein 4 RTP4. In-vitro experiments showed that this protein participates in folding of d-m receptor heterodimers, enhancing the trafficking of d-m receptor complexes from the Golgi apparatus to the cell surface and decreasing the expression of d monomers (Decaillot et al., 2008) . Future experiments will determine whether these processes occur in vivo.
Receptor activity at the cell surface
Receptor activity is also modulated at the plasma membrane, through interactions with other membrane proteins. In particular, d receptors may associate with other G protein-coupled receptors (GPCRs) to form heterodimers or larger heteromers at the cell surface. On the basis of several approaches and criteria used to define potential GPCR heterodimers (see Massotte, 2010) , d receptors have been proposed to interact with GPCRs implicated in pain control, including m and k opioid receptors (Gupta et al., 2010; Kabli et al., 2010; Van Rijn et al., 2010) , CB1 cannabinoid receptors (see Bushlin et al., 2010) and a2-adrenergic receptors (see Van Rijn et al., 2010) . Delta receptors may also interact with chemokine receptors (Parenty et al., 2008; Pello et al., 2008) with potential consequences on inflammation, including inflammatory pain (Chen et al., 2007) . These studies, mainly performed in heterologous cell recombinant systems, show new pharmacological properties for d receptor-GPCR heterodimers (reviews Bushlin et al., 2010; Rozenfeld and Devi, 2010; Van Rijn et al., 2010) . Opioid receptor heterodimers may also be involved in the activities of bifunctional opioid drugs investigated as novel classes of analgesics (Ansonoff et al., 2010; Schiller, 2010) .
Receptor activation and intracellular effectors
Finally, receptor density and activity at the cell surface is tightly regulated by intracellular effectors, which engage the receptor into both signaling and trafficking processes upon activation. The best-known signaling effectors of the d receptor are inhibitory heterotrimeric Gi/o proteins, which further modulate ion channels and second messengers leading ultimately to reduced neuronal activity (Williams et al., 2001) . In addition to signaling, agonist binding to the receptor also induces phosphorylation, internalization, trafficking and redistribution of the receptor, and these events represent key mechanisms for the regulation of receptor activity Ritter and Hall, 2009 ). Unlike the m opioid receptor, which rapidly recycles to the cell surface, d receptors are targeted towards lysosomal degradation (Pradhan et al., 2009 ) through the endosomal sorting complex required for transport machinery, using ubiquitination-dependent or independent mechanisms (Henry et al., 2010) . Other factors upstream of the endosomal sorting complex required for transport pathway also contribute to d receptor proteolysis, including G protein-coupled receptor Associated Sorting Proteins shown to interact with the d receptor (Abu-Helo and Simonin, 2010; Moser et al., 2010) .
The link between agonist-induced internalization, downregulation and in-vivo function of d receptors was investigated using the DOR-eGFP mouse model (Pradhan et al., 2009 (Pradhan et al., , 2010 . Data indicated that a single injection of a high (SNC80) and a low (AR-M100390)-internalizing compound to DOR-eGFP mice produced equally efficient analgesia in a model of inflammatory pain. SNC80 also concomitantly induced receptor internalization throughout the nervous system, accompanied by G-protein uncoupling and acute behavioral desensitization, such that a second drug injection was inefficient.
Receptor desensitization was transient and receptor responsiveness returned to basal levels after one day. In contrast, AR-M100390 induced none of the regulatory responses, as no internalization, G-protein uncoupling or acute desensitization were detectable (Pradhan et al., 2009) . Interestingly further chronic treatment with the two agonists both induced the development of tolerance, but the expression of tolerance differed. The highinternalizing agonist (SNC80) induced generalized tolerance, so that all agonist effects were blunted in chronically-treated mice, and the low-internalizing agonist (AR-M100390) produced a partial tolerance that was restricted to analgesic responses, whereas anxiolytic or locomotor effects of d agonists remained intact (Pradhan et al., 2010) . This set of data is in accordance with previous in-vitro studies showing ligand-specific conformational changes of the d receptor (Audet et al., 2008) and definitely establish the in-vivo relevance of d receptor ligand-biased agonism in drug efficacy. The critical consequences of biased agonism at the d receptor add further physiological support to the rapidly growing field of functional selectivity at GPCRs (Bosier and Hermans, 2007; Galandrin et al., 2007; Mailman, 2007; Vaidehi and Kenakin 2010; Zheng et al., 2010) and may be considered for the development of effective therapeutic drugs.
Functional interactions between delta and other neuromodulatory systems.
An active research field is the elucidation of respective contributions of m and d receptors in nociceptive processing, particularly to control heat and mechanical pain modalities (Basbaum et al., 2009; Scherrer et al., 2009; Woolf, 2009) , and the identification of molecular and cellular mechanisms underlying functional interactions between the two receptors. Interactions may occur either at cellular or system levels within nociceptive pathways. This has been extensively discussed in the past (Zaki et al., 1996; Kieffer, 1999; Smith and Lee, 2003) and more recent anatomical analysis has provided evidence for potential interactions at the cellular level in vivo. Data from in-situ mRNA hybridization (Mansour et al., 1995; Wang and Wessendorf, 2001; Mennicken et al., 2003) , the analysis of DOR-eGFP mice , and local pharmacology in peripheral neurons (Joseph and Levine, 2010) suggest that m and d receptors may be colocalized in a limited number of peripheral nociceptor neurons. This coexpression opens the possibility for within-cell functional interactions in primary nociceptive processing, which may occur between receptors or their downstream signaling pathways. Delta and m receptor colocalization in the dorsal spinal cord remains debated Scherrer et al., 2009; Wang et al., 2010) .
A large array of evidence indicates that d receptor function is increased either after chronic morphine or under conditions of chronic pain. A suggested common basis for this phenomenon lies in the observation of increased d receptor density at the cell surface in both cases, leading to higher number of receptors available for activation (Bie and Pan, 2007; Cahill et al., 2007; Morgan et al., 2009; Schramm and Honda, 2010) . In the case of chronic morphine, the enhancement of d receptor function likely involves a functional link between m receptor activation and d receptors, whose mechanism remains open (see above). In situations of persistent pain, other mechanisms involving bradykinin (Patwardhan et al., 2005) , protease activated receptor-2 (Patwardhan et al., 2006) , arachidonic acid (Rowan et al., 2009 ) and nerve growth Factor (Bie et al., 2010) have been shown to augment d receptor activity. Collectively, interactions between d receptors and several other opioid or nonopioid receptor systems have been reported to influence d opioid analgesia, and a great diversity of GPCRs involved pain control (Pan et al., 2008; Stone and Molliver, 2009 ) may potentially interact with, or modulate, d receptor analgesic activity.
Conclusion
The field of d opioid receptor analgesia has benefited from recent contributions in pharmacology, molecular, and cellular approaches. Novel selective d agonists with potent in-vivo activities are now available to strengthen approaches targeting d receptors. The field of d receptors and pain control may also benefit from the development of animal models more closely related to clinical pain (Finley et al., 2008) . In particular the evaluation of d receptor activity in spontaneous pain and in the emotional or affective dimensions of pain (King et al., 2009; Minami, 2009 ) may provide new elements for the development of d receptor-based therapeutic strategies.
